Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3578926"]Endo partners with ProStrakan to market testosterone transdermal gel</p><p>Posted on: Thu, 27 Aug 2009 05:09:00 EDT</p><p><br /></p><p>Aug 27, 2009 (Datamonitor via COMTEX) --</p><p>PKNGF | Quote | Chart | News | PowerRating -- US-based Endo Pharmaceuticals has signed an agreement with ProStrakan Group, a UK-based specialty pharmaceutical company, for the exclusive right to commercialize Fortesta 2% in the US.</p><p><br /></p><p>Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones.</p><p><br /></p><p>Endo Pharmaceuticals has also agreed to pay ProStrakan an additional $160 million upon the achievement of certain sales targets. ProStrakan will exclusively supply Fortesta to Endo Pharmaceuticals in the US for an undisclosed supply price.</p><p><br /></p><p>Fortesta, a patented 2% testosterone transdermal gel for testosterone replacement therapy</p><p>in male hypogonadism, utilizes a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is in registration in the US, where the FDA is currently reviewing ProStrakan's new drug application submission.</p><p><br /></p><p>David Holveck, president and CEO of Endo Pharmaceuticals, said: "We are committed to advancing men's health with effective new medicines. Being in a position to potentially offer this treatment, alongside our new long-acting injectable testosterone product, will help fill an important gap in testosterone replacement. This treatment option is synergistic with our recent therapeutic expansion and strengthens our portfolio in urology and endocrinology."[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3578926"]Endo partners with ProStrakan to market testosterone transdermal gel Posted on: Thu, 27 Aug 2009 05:09:00 EDT Aug 27, 2009 (Datamonitor via COMTEX) -- PKNGF | Quote | Chart | News | PowerRating -- US-based Endo Pharmaceuticals has signed an agreement with ProStrakan Group, a UK-based specialty pharmaceutical company, for the exclusive right to commercialize Fortesta 2% in the US. Under the terms of the agreement, Endo Pharmaceuticals has agreed to make an upfront payment to ProStrakan of $10 million, with the potential for up to $40 million more in milestone payments by the end of 2010 for regulatory approval and the achievement of certain commercial milestones. Endo Pharmaceuticals has also agreed to pay ProStrakan an additional $160 million upon the achievement of certain sales targets. ProStrakan will exclusively supply Fortesta to Endo Pharmaceuticals in the US for an undisclosed supply price. Fortesta, a patented 2% testosterone transdermal gel for testosterone replacement therapy in male hypogonadism, utilizes a metered dose delivery system designed to permit accurate dose adjustment to individual patient requirements. This product is in registration in the US, where the FDA is currently reviewing ProStrakan's new drug application submission. David Holveck, president and CEO of Endo Pharmaceuticals, said: "We are committed to advancing men's health with effective new medicines. Being in a position to potentially offer this treatment, alongside our new long-acting injectable testosterone product, will help fill an important gap in testosterone replacement. This treatment option is synergistic with our recent therapeutic expansion and strengthens our portfolio in urology and endocrinology."[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Endo
>
Fortesta - testosterone gel for Urology
>